Vizient is set to acquire Intalere from Intermountain Healthcare to strengthen its stake in the healthcare supply chain market.
“This acquisition builds on the strengths of both Vizient and Intalere and furthers our ability to meet the growing needs of the increasingly diverse range of members and customers we serve," said Byron Jobe, Vizient’s president and chief executive officer, in a statement.
The acquisition expands Vizient’s non-acute footprint to create more opportunities through the Vizient subsidiary, Provista, and increases its presence in smaller and rural acute facilities. This will garner greater support for these communities with local healthcare services, while aligning cost, quality and market performance.
It also is partnering with Intermountain Healthcare in a collaboration that builds on their relationship in clinical and cost analytics. “Intermountain Healthcare looks forward to continuing to work together with Vizient in our common goal of providing patients access to high-quality care at the most affordable cost,” said Bert Zimmerli, chief financial officer and executive vice president at Intermountain. “This aligns very well with our aspiration of executing a population health strategy by providing value-based care and services to an increased number of patients, families, and communities.”
The news follows another partnership struck up just this month between Intalere and MXR Imaging
. The collaboration between the two gives Intalere members access to reconditioned diagnostic imaging equipment at negotiated prices, as well as clinical engineering training programs for in-house service teams, education programs to help providers service their equipment internally, vendor- and equipment-specific classes for ultrasound, MR and CT, and customized on-site training courses.
Vizient manufactures solutions that align cost, quality and market performance to strengthen delivery of care. It caters to more than 50% of acute care providers in the U.S., including 95% of the nation’s academic medical centers, and more than 20% of ambulatory providers.
The deal is expected to close during Q1 2021, pending standard regulatory review.
No financial details have been disclosed.